FindTrial
Sign In

Whole Body Cryotherapy (WBC) for treating anosmia / hyposmia

Whole-Body Cryotherapy (WBC) for COVID-19 recovered patients having anosmia or severe hyposmia

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT20210708051817N1
Enrollment
42
Registered
2021-07-14
Start date
2021-02-01
Completion date
Unknown
Last updated
2021-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 induced anosmia or severe hyposmia (defined as more than 50 percent of loss of sense of smell). U07.1 COVID-19, virus identified

Interventions

Intervention 1: Intervention group 1: high-dose Whole-Body Cryotherapy (WBC). Participants receive daily sessions of WBC in a cryotherapy chamber at temperature of -90°C. Sessions are 3 minutes in len

Sponsors

The University of Reims Champagne Ardenne
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 79 Years

Inclusion criteria

Inclusion criteria: recovered COVID-19 patients (asymptomatic for at least 3 weeks) anosmia or severe hyposmia (more than 50 percent reduction of olfactory acuity)

Exclusion criteria

Exclusion criteria: medical contraindications to Whole-Body Cryotherapy

Design outcomes

Primary

MeasureTime frame
Participant's score change on the Visual Analog Scale measuring the loss of sense of smell. Timepoint: the day before and the day following intervention. Method of measurement: participant's self-report evaluation on a Visual Analog Scale 0-100 ; with "0" indicating complete loss of sense of smell compared to what it was before being infected by COVID-19; and"100" indicating full recovery of sense of smell.—

Countries

France

Contacts

Public ContactFabien Legrand

The University of Reims Champagne Ardenne

fabien.legrand@univ-reims.fr+33 3 26 91 38 90

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026